More on BFRI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+75.8% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Biofrontera Inc. (NQ:BFRI)
Delayed: 0.79 +0.01 (1.28%)
Prev. Close $0.78  
Open$0.80 
52 Wk High$ 
52 Wk Low$ 
Day High$0.81 
Day Low$0.78 
P/E N/A  
EPS$ 
Volume112,869 

Friends, Peers and Foes (?): BFRIW (more...)

Oct 8, 2026 09:22 AM Biofrontera files sNDA to expand Ameluz use to full-body skin lesions
Oct 8, 2026 09:22 AM Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Sep 15, 2026 07:31 AM Biofrontera (BFRI) Reiterated at Speculative Buy by StoneX as Ameluz Approved For sBCC
Sep 14, 2026 09:30 AM Form 8-K Biofrontera Inc. For: Sep 14
Sep 14, 2026 09:26 AM FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma
Sep 14, 2026 09:26 AM Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Aug 13, 2026 04:41 PM Form 10-Q Biofrontera Inc. For: Jun 30
Aug 13, 2026 09:01 AM Form 8-K Biofrontera Inc. For: Aug 13
Aug 13, 2026 08:51 AM Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Aug 12, 2026 02:31 PM Form SCHEDULE 13G/A Biofrontera Inc. Filed by: Rosalind Advisors, Inc.
View All Articles

Entities mentioned with BFRI

View All Entities